iOnctura

Biotech & Life Sciences · Geneva, Switzerland · Founded 2017

Developer of next-generation bio-molecules intended for the treatment of cancer and fibrosis. The company's bio-molecules include novel therapeutics that modulate key culprits of immunosuppression in the tumor microenvironment, enabling doctors to treat diseases such as cancer faster. Keywords: Healthcare Devices, Services, Supplies, Biomolecule Drugs, Biopharmaceutical Research, Cancer Drug, Cancer Treatment, Fibrotic Diseases Drugs, Oncology Treatment.

Valuation $100–500M

Headcount <100

Total funding $100–500M

Unlock exact values

Investors

14 investors on iOnctura's cap table

Sourced from Dealroom's funding history.

Seed 3 investors entered at this stage

European Innovation Council

Health Holland

KWF Kankerbestrijding

Series A 9 investors entered at this stage

M Ventures

Inkef

VI Partners

Schroder Adveq

3B Future Health Fund

EIC Fund

Syncona

Merck Ventures

Schroders Capital

Series B+ 2 investors entered at this stage

Merck KGaA

FONGIT

Global footprint

Where iOnctura has talent and traffic

Workforce by country

5 countries with
team presence

🇨🇭 Switzerland46.1%

🇬🇧 United Kingdom19.2%

🇳🇱 Netherlands11.5%

🇩🇪 Germany11.5%

🇺🇸 United States11.5%

5 countries shown

Talent graph

The shape of iOnctura's talent

Dealroom maps iOnctura's team person by person — pinpointing the standout operators and scoring them across the six dimensions investors underwrite. The counts and shape below are a public preview; the named individuals and exact scores live in the platform.

13 team members profilednamed & role-tagged by Dealroom

34 employeestotal headcount

6 executives & foundersidentified by name

DimensionScore

AI Talent

Engineering

Product

Go-to-market

Leadership

Research

Book a demo to unlock iOnctura's exact scores

Source: Dealroom Talent Intelligence. Public profiles show counts and the team's shape only — request a demo for the named individuals, per-person seniority and tenure, and team benchmarks vs peers.

Market sentiment

What the market is saying about iOnctura

An AI-synthesized read of the highest-engagement posts about iOnctura on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See iOnctura on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

Book a demo Explore company profiles